SUBSCRIBE
SUBSCRIBE

Merck & Co.

AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
NEWS
Deals
Paper: Novartis Eyes Big U.S. Acquisition
October 19, 2005
 · 
1 min read
Will Biotech Cure Heart Disease?
October 19, 2005
 · 
1 min read
Business
Merck CEO Vows Support To Schering-Plough Venture
October 19, 2005
 · 
1 min read
Drug Development
Striving To Stop HIV
October 19, 2005
 · 
1 min read
BioMidwest
Cholesterol Drugs May Reduce Colon Cancer Risk
October 19, 2005
 · 
1 min read
BioCapital
Biotech’s Hype And Hope Yielded Losses
October 19, 2005
 · 
1 min read
Load More
JOBS
IN THE PRESS
Press Releases
Merck to Participate in the TD Cowen 46th Annual Health Care Conference
February 24, 2026
 · 
3 min read
Press Releases
Merck Evolves Human Health Operating Structure to Support Portfolio Execution
February 23, 2026
 · 
5 min read
Press Releases
Merck Announces Positive New Data for ENFLONSIA™ (clesrovimab) for Infants and Children Under 2 Years of Age at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease Over Two RSV Seasons
February 19, 2026
 · 
12 min read
Press Releases
Merck and Mayo Clinic Announce New Research and Development Collaboration to Support AI-Enabled Drug Discovery and Precision Medicine
February 18, 2026
 · 
5 min read
Press Releases
Health Canada Approves KEYTRUDA SC™, a subcutaneous formulation of pembrolizumab across multiple cancer indications
February 17, 2026
 · 
7 min read
Press Releases
Merck Advances Treatment of Bladder and Kidney Cancers with New Data at 2026 ASCO GU Cancers Symposium
February 12, 2026
 · 
19 min read
Press Releases
KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ≥1) Platinum-Resistant Ovarian Carcinoma as Second or Third Line Treatment
February 11, 2026
 · 
19 min read
Press Releases
Calla Lily Clinical Care and Merck Announce Strategic Collaboration to Advance Intravaginal Drug Delivery Platform
February 10, 2026
 · 
3 min read
Press Releases
Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
February 8, 2026
 · 
4 min read
Press Releases
Merck Announces Health Canada Approval of ENFLONSIA® for the prevention of RSV in newborns and infants
February 5, 2026
 · 
6 min read
Load More